A Texas researcher received a $219,000 NIH grant to study the potential of a treatment for radiation-induced pulmonary fibrosis.

Clinical trials are an important part of IPF research, says columnist Sam Kirton, but we need people willing to participate in them.

Over the coming months, the Pulmonary Fibrosis Foundation's 2025 PFF Walk will aim to raise more than $1 million for the ...

Living with pulmonary fibrosis, columnist Ann Reynoso writes, means no more independent, spontaneous days with enough energy ...

During the dog days of summer, columnist Sam Kirton takes special care to protect himself from medication side effects.

That’s according to top-line data from the Phase 2b CORAL trial (NCT05964335), which is evaluating three doses of the experimental oral therapy against a placebo, taken twice a day, in 165 adults.

FIBRONEER-IPF (NCT05321069) enrolled 1,177 IPF patients, while FIBRONEER-ILD (NCT05321082) enrolled 1,176 adults with progressive forms of pulmonary fibrosis other than IPF. Because the studies met ...

A Phase 2 clinical trial has begun recruiting that’s assessing the safety and efficacy of LTI-03, Rein Therapeutics’ inhaled therapy for idiopathic pulmonary fibrosis (IPF). RENEW (NCT06968845) is ...

GRI Bio has reached an interim enrollment goal for its Phase 2a clinical trial testing GRI-0621 — a therapy targeting natural killer T-cells (NKT cells) to treat idiopathic pulmonary fibrosis (IPF) — ...

In people with IPF, however, senescence markers are more abundant than in healthy individuals, and the abnormal persistence of these cells has been linked to inflammation and scar tissue formation..